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Autophagy is a conserved biological stress response in mammalian cells that is responsible for clearing damaged proteins
and organelles from the cytoplasm and recycling their contents via the lysosomal pathway. In cases of mild stress, autophagy
acts as a survival mechanism, while in cases of severe stress cells may switch to programmed cell death. Understanding the
decision process that moves a cell from autophagy to apoptosis is important since abnormal regulation of autophagy occurs
in many diseases, including cancer. To integrate existing knowledge about this decision process into a rigorous, analytical
framework, we built a mathematical model of cell fate decisions mediated by autophagy. Our dynamical model is consistent
with existing quantitative measurements of autophagy and apoptosis in rat kidney proximal tubular cells responding to
cisplatin-induced stress.
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Autophagy and its dysregulation play important roles in the
pathogenesis of many complex diseases.1 For instance,
autophagy helps cancer cells to survive the stresses of
nutrient deprivation and anoxia.2 Autophagy is also involved
in the development of resistance to chemotherapy; inhibi-
ting autophagy can increase the therapeutic responses of
resistant cancer cells to chemotherapy, endocrine therapy,
or radiation therapy.3,4 While autophagy is normally initiated
as a prosurvival response to stress, excessive stress can
trigger cell death.
Recently, we proposed a systems biology approach to
model the complex interplay among pathways for estro-
gen and growth factor signaling, unfolded protein
response (UPR) stress, autophagy, and apoptosis in the
context of breast cancer responses to endocrine therapy.5
Other authors as well have argued that mathematical the-
ories of the systems-level properties of molecular signal-
ing networks will play pivotal roles in the emerging field
of systems pharmacology.6 In particular, several mathemat-
ical models of autophagy have been proposed recently.
Martin et al.7 presented a computational model of auto-
phagic vesicle dynamics in single cells, but they did not
address the crucial interplay between autophagy and apo-
ptosis. Kapuy et al.8 addressed this interplay using a sim-
plified mathematical model, but they did not compare their
simulations with experimental measurements of how cells
respond to stress. Our motivation for building mathematical
models of autophagy and apoptosis is to integrate current
mechanistic knowledge of these processes into a coherent
framework and to determine if the mechanisms we include
can explain existing qualitative observations and quantita-
tive data on autophagic responses of cells to stress. As
more data become available, this model can serve as a
foundation for better models, with the goal of accurately
predicting how therapeutic interventions may alter cell fates
in normal and diseased tissues.
MOLECULAR CELL BIOLOGY OF AUTOPHAGY AND
APOPTOSIS
Autophagy is a conserved catabolic cellular process by
which a cell degrades its own components, including dam-
aged proteins and organelles. Autophagosomes (subcellular
organelles enclosed by two or more membranes) engulf
damaged materials, fuse with lysosomes, and the resulting
autolysosome then uses lysosomal enzymes to degrade
the contents of the autophagic vacuoles.1 Autophagy-
related proteins (ATG proteins) drive autophagosome for-
mation in yeast and mammalian cells.1,9 Commitment of a
cell to autophagy seems to occur at the earliest stages of
vesicle nucleation and formation of the isolation membrane,
a small, flattened membrane sac that elongates and curves
to create an autophagosome.1,9
Major molecular players in the induction of autophagy in
mammalian cells are mTOR (the mammalian target of rapa-
mycin) and ATG13. mTOR is a signal integrator that senses
stress conditions such as endoplasmic reticulum (ER)
stress, hypoxia, low growth factor levels, or low levels of
essential amino acids.10 When there are no critical stress
conditions in the cell, a protein complex consisting of mam-
malian ATG13, Unc-51-like autophagy activating kinase 1
(ULK1, the mammalian homolog of yeast Atg1), and focal
adhesion kinase interacting protein of 200 kD (FIP200)
is repressed by mTOR phosphorylation of ATG13 and
ULK1. Cellular stress inactivates mTOR, allowing the
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ULK1:ATG13:FIP200 complex to be active.11 The active
complex promotes formation of the isolation membrane.
Beclin-1, the mammalian ortholog of yeast Atg6, is nec-
essary for autophagosome formation, playing a key role in
vesicle nucleation.1,9 BCL-2 family proteins in the ER func-
tion as antiautophagy proteins through their inhibitory bind-
ing with Beclin-1. Although Beclin-1 contains a BCL-2
homology domain 3 (BH3), it is not proapoptotic.1,12 For
autophagosome formation to begin, Beclin-1 must be
released from BCL-2 inhibition, which is promoted by either
phosphorylation of BCL-2 by c-Jun N-terminal kinase
(JNK), or by phosphorylation of Beclin-1 by death-
associated protein kinase (DAPK).13–16 Free Beclin-1 then
binds with other partners to form a “Beclin-1 core complex,”
which promotes vesicle nucleation.1,9
For more details about the physiology and molecular biol-
ogy of autophagy, we refer the reader to our review article.3
A convenient quantitative measure of autophagosome
formation in mammalian cells is the state of microtubule-
associated protein light chain 3 (LC3),17 which is a mam-
malian homolog of yeast Atg8. LC3 exists in two forms:
LC3-I (cytosolic form, 18 kDa) and LC3-II (membrane-
bound form, 16 kDa). After autophagy initiation, LC3-I is
converted to LC3-II, which then participates in the vesicle
elongation step of autophagosome formation.1,17 LC3-II can
be distinguished from LC3-I by immunoblotting. Alterna-
tively, autophagosome formation can be visualized as green
“puncta” by tagging LC3 with green fluorescent protein.18
In contrast to autophagy, the molecular regulatory system
that controls apoptosis is reasonably well understood. The
extrinsic and intrinsic signaling pathways leading to
caspase-dependent apoptosis have been studied by mathe-
matical modeling.5,19,20 We focus on the intrinsic pathway,
which leads to mitochondrial outer membrane permeabiliza-
tion (MOMP), causing release of cytochrome C into the cyto-
plasm and subsequent activation of executioner caspases.
The induction of MOMP is dependent on oligomerization of
proapoptotic proteins (BAX or BAK) in the outer mitochon-
drial membrane, while antiapoptotic BCL-2 family proteins in
the mitochondria inhibit these proapoptotic proteins. Activa-
tion of BAX and BAK is triggered by BH3-only proteins.1,19
Crosstalk between autophagy and apoptosis
BCL-2 family proteins in the ER and mitochondria are
important regulators of autophagy and apoptosis, respec-
tively.21,22 Hence, different levels of expression of BCL-2
proteins in the ER membrane and in the mitochondrial
membrane may lead to different activation dynamics for
autophagy and apoptosis. Calcium signaling from the ER to
mitochondria may also play a role in autophagy-apoptosis
crosstalk.21–25 The inositol-1,4,5-trisphosphate receptor
(IP3R) and the sarco/endoplasmic reticulum Ca21-ATPase
(SERCA) pump are the central regulators of Ca21
exchange between ER and cytoplasm. By pumping Ca21
from the cytosol into the ER, SERCA is responsible for
maintaining very low calcium ion concentrations in the cyto-
plasm. Conversely, IP3R is a stress-activated Ca21 channel
that releases Ca21 from the ER into the cytoplasm.22–26
Normally, IP3R is sequestered by BCL-2 family proteins in
the ER membrane.27 Phosphorylation of BCL-2 proteins dis-
sociates the complex and allows for calcium release from
the ER.28 Sustained, elevated cytoplasmic Ca21 can lead to
apoptosis.22,23,29 Cytoplasmic Ca21 can also inhibit mTOR
via activation of calmodulin-dependent kinase kinase-b
(CaMKKb), which activates AMPK (50 AMP-activated protein
kinase). AMPK has an inhibitory effect on mTOR.30
Calcium influx into mitochondria can induce apoptosis
directly, and several other signaling pathways also link sus-
tained calcium elevation to apoptosis.22,23,29,31,32 For exam-
ple, calcium activates calcineurin, which dephosphorylates
and activates BAD, a proapoptotic BCL-2 family protein capa-
ble of inducing apoptosis.33 In addition, calcium can activate
calpain, a cysteine protease that cleaves ATG5, an essential
protein for autophagosome formation. Truncated ATG5 indu-
ces apoptosis by suppressing antiapoptotic BCL-2 proteins in
the mitochondria.1,34,35 The mechanism of this suppression is
unknown; so, for modeling purposes, we assume that trun-
cated ATG5 upregulates proapoptotic BH3 proteins. During
apoptosis, the activation of caspase 8 downregulates auto-
phagosome formation by cleaving Beclin-1.36–38
For more details about the interplay of autophagy and
apoptosis, we refer the reader to the excellent review article
by Marino et al.39
METHODS: MATHEMATICAL MODELING APPROACH
From these facts we draw an “influence diagram” (Figure 1),
which summarizes our hypothesis about the most relevant
molecular interactions between autophagy and apoptosis in
mammalian cells. In Supplementary Text S1, we convert
this influence diagram into a mathematical model. Our math-
ematical model is formulated in terms of 21 variables
(Table 1) whose response to stress is described by the differ-
ential and algebraic equations in Table 2. The equations
were solved numerically using the MatLab code (MathWorks,
Natick, MA) in Supplementary Text S2. As described in
Supplementary Text S3, we fitted model simulations to
experimental data (Supplementary Table S1) to obtain the
“optimal” set of parameter values in Table 3. Using these
optimal parameter values, we computed the steady-state val-
ues of all variables under no-stress conditions (C 5 0; see
Table 1). These values were used as initial conditions for
simulations of how cells respond to stress (C > 0).
To examine the generic properties of our model, we solve
the governing equations for fixed (optimal) values of the
parameters and varying levels of stress, C. These simula-
tions represent how an “average” cell might respond to
stress, but they cannot be compared to the observed
behavior of a population of cells responding to cisplatin,
because, in the latter case, we must take into account the
heterogeneous response of cells to apoptotic signals. We
attribute this heterogeneity to differences among cells in
the mitochondrial concentration of BCL2, because (in our
model) this parameter most sensitively determines whether
or not apoptosis occurs, and if so, when. Using randomly
selected [BCL2mit] levels from a lognormal distribution, we
simulate 100 cells and record the average value of every
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variable, including the percentage of cells having under-
gone apoptosis at each timepoint.
Although we attribute cellular heterogeneity entirely to
fluctuations in [BCL2mit], this assumption is clearly an over-
simplification. Other sources of variability, e.g., in BH3 pro-
duction or ATG5 cleavage, may well contribute to the
variable commitment of cells to apoptosis. Nonetheless, our
assumption is a simple and effective way to fit the model to
experimental observations of percent apoptosis.
Before we can compare our model to data (which has
some level of uncertainty), we must quantify how uncertain
we are about the optimal parameter values given in
Table 3. To this end, we describe, in Supplementary Text
S3, how we perturbed the optimal set of parameter values
to obtain alternative sets of parameter values that provide
“acceptable” fits of model simulations to the experimental
data. We created a collection of 3,758 “acceptable sets of
parameter values” and all simulations of experimental data
are based on samples from this collection. In this way we
take into account our uncertainty about the parameter val-
ues and the consequent range of predictions that are made
by the model. In Table 3 we record the coefficient of
Table 1 Variables, their descriptions, and their values when cisplatin 5 0
Variable Description
Steady-state value
(no drug treatment)
[ATG5] Concentration of active ATG5 0.717
[tATG5] Concentration of truncated ATG5 0.283
[ATG13] Concentration of active ATG13 protein 0.0184
[ATPHG] Concentration of autophagosomes in cytoplasm 0.285
[BCL2]U Concentration of unphosphorylated BCL-2 family proteins in ER 2.463
[BCL2_P] Concentration of phosphorylated BCL-2 family proteins in ER 0.537
[BECN1]T Concentration of total Beclin-1 protein 3
[BECN1_P] Concentration of phosphorylated Beclin-1 protein 0.0382
[BECN1]F Concentration of Beclin-1 protein free from suppression by BCL-2 1.121
[BECN1]U Concentration of unphosphorylated form of Beclin-1 protein 2.962
[BH3] Concentration of active BH3 proteins 0.0690
[Ca21] Concentration of cytoplasmic Ca21 0.397
[CALPAIN] Concentration of active CALPAIN 0.0221
[CASP] Concentration of active caspase 0
[DAPK] Concentration of active death-associated protein kinase 0.103
[IP3R]F Concentration of IP3 receptors free from suppression by BCL-2 0.378
[JNK] Concentration of active c-Jun N-terminal kinase 0.281
[LIG]T Concentration of total ligands available for binding to BCL-2 in ER 3.962
[LIG]F Concentration of ligands free from suppression by BCL-2 1.499
[MTOR] Concentration of active mammalian target of rapamycin (mTOR) 0.335
S Level of stress induced in the cell by drug treatment or other stressors 0.831
Figure 1 The interplay between autophagy and apoptosis. (a) Diagram of the “influences” (activation 5 barbed arrows, inhibition 5
blunt arrows) between the major proteins controlling autophagosome formation and apoptosis. (b) More detailed diagram of the reac-
tions involved in the dashed box in panel a. Solid arrows 5 chemical reactions; dashed arrows 5 catalytic activities; T-junctions 5
reversible formation of a binary complex.
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variation (CV 5 standard deviation/jmeanj) of each param-
eter value over the collection of acceptable parameter sets.
These CV’s fall in the range 8%–19%.
RESULTS
The experimental data we seek to explain involve the
response of rat kidney proximal tubule (RPT) cells to treat-
ment with cisplatin, a widely and effectively used antineo-
plastic drug. Cisplatin induces the UPR and activation of
JNK and DAPK in mammalian cells.40–42 Periyasamy-
Thandavan et al.18 used RPT cells, transiently transfected
with GFP-LC3 and treated with cisplatin, to investigate the
cytoprotective role of autophagy. To study the time course of
autophagosome formation, the investigators measured tem-
poral changes in cisplatin-induced LC3 puncta by fluores-
cence microscopy, and LC3-II production by immunoblotting.
They also measured the autophagic response and the per-
centage of apoptotic cells when RPT cells were treated with
cisplatin in the presence or absence of bafilomycin (BAF)
and 3-methyladenine (3-MA), which are inhibitors of autoph-
agy. To compare our model calculations with experimental
data, we equated the autophagy level in our model,
[ATPHG], with the LC3-II level measured by immunoblotting.
Programmed cell death in our model is associated with an
“indicator function” [CASP], which takes the value 0 in living
cells and the value 1 when a cell commits to apoptosis,
which occurs as soon as [BH3] exceeds [BCL2mit].
Generic properties of the model
The behavior of an “average” cell to cisplatin-induced stress
is predicted by simulating the equations in Table 2 with the
optimal parameter values in Table 3 (with [BCL2mit] fixed at
0.12), starting from the steady-state initial conditions in
Table 1. In Figure 2a,b we show how 13 of our variables
change over the course of time for an average cell
responding to a continuous dose of cisplatin, C 5 20 in the
model. (For time courses of all variables in the model, see
Supplementary Figure S1.) Most changes occur within
the first few hours, as the cells quickly activate autophagy
to respond to the stress. Then, at t 5 18 hours, executioner
caspases are activated and the autophagic response
switches off (Figure 2c) as the cell becomes apoptotic.
These general characteristics of the response are consist-
ent with the behavior of cells exposed to 20 lM cisplatin.18
Indeed, parameter values in the model are chosen so that
simulation results at C 5 20 correspond to experimental
results at a cisplatin dose of 20 lM.
In Figure 2c we show how the level of autophagy, over
the course of 4 days, responds to a range of cisplatin doses
up to C 5 100. For low doses, [ATPHG] rises quickly (6–8
hours) to a steady-state level, in order to counteract the
stress caused by cisplatin. For larger doses, [ATPHG] rises
quickly but then falls to zero as BH3 proteins accumulate in
the overstressed cells, which commit apoptosis when
[BH3] 5 [BCL2mit] 5 0.12. In Figure 2c, one can see the
activation of apoptosis as a kink in [ATPHG](t) when [CASP]
switches from 0 to 1. For C 5 100, 20, and 6, CASP is
activated at t 5 7.5, 18, and 59 hours, respectively. The apo-
ptotic response (in our model) is driven primarily by calpain-
dependent ATG5 cleavage, which dials back the production
of autophagosomes and produces proapoptotic, truncated
ATG5 molecules. Presumably these effects are intended to
force cells to commit to apoptosis under conditions of high
stress. Caspase activation cleaves Beclin-1 and turns off for-
mation of autophagosomes. Beyond this timepoint, the
remaining autophagosomes fuse with lysosomes and are
degraded, with [ATPHG] ultimately decaying to zero.
In Figure 2d we repeat this simulation for a population of
100 cells with [BCL2mit] following a lognormal distribution
and plot the population-average level of autophagy at t 5
100 hours. (We simulate to t 5 100 hours to be reasonably
sure that the dynamical model has reached its steady-state
response.) For C < 5, autophagy ramps up with stress level
and most cells survive. For 5 < C < 6, the average level of
autophagy drops with increasing C because some—but not
all—cells in the population die. For C > 6, all cells in the
population are dead by t 5 100 hours. To explore this switch
between autophagy and apoptosis more closely, we plot (in
Figure 2e) the percent apoptosis as a function of cisplatin
dose at various timepoints from 6 hours to 100 hours.
Table 2 Equations defining the model
Differential Equations:
d ½ATG5
dt 5cA  ðF ðrAWAÞ2½ATG5Þ
d ½ATG13
dt 5cG  ðF ðrGWGÞ2½ATG13Þ
d ½ATPHG
dt 5ka  ð½BECN1F1½BECN1 PÞ½ATG13½ATG52kda  ½ATPHG
d ½BCL2 P
dt 5cB  ð½BCL2ER   F ðrBWBÞ2½BCL2 PÞ
d ½BECN1T
dt
52kcasp  ½CASP  ½BECN1T
d ½BECN1 P
dt 5cL  ð½BECN1T  F ðrLWLÞ2½BECN1 PÞ
d ½BH3
dt 5cH  ðF ðrHWHÞ2½BH3Þ
d ½Ca21 
dt 5kout  ½IP3RF  ð½Ca21T2½Ca21Þ2kin  ½Ca21
d ½CALPAIN
dt 5cC  ðF ðrCWCÞ2½CALPAINÞ
d ½DAPK
dt 5cD  ðF ðrDWDÞ2½DAPKÞ
d ½JNK
dt 5cJ  ðF ðrJWJÞ2½JNKÞ
d ½MTOR
dt 5cT  ðF ðrTWTÞ2½MTORÞ
dS
dt 5kc  C1ksb2ðkrb1kra  ½ATPHGÞ  S
Algebraic Equations:
½tATG5512½ATG5
½BCL2U 5½BCL2ER2½BCL2 P
½BECN1U 5 ½BECN1T2½BECN1 P
½LIGT5½IP3RT1½BECN1U
½LIGF5maxð0; ½LIGT2½BCL2u)
½IP3RF5½IP3RT  ½LIGF½LIGT
½BECN1F5½BECN1U  ½LIGF½LIGT
½CASPð0Þ50; ½CASPðtÞ51 when ½BH35 ½BCL2mit and ever thereafter
Definitions:
F ðxÞ5 111e2x
WA5wATG5 02½CALPAIN
WB52wBCL2P 01½JNK
WC52wCALP 01½Ca21
WD52wDAPK 01S
WG5wATG13 02½MTOR
WH52wBH3 01wBH3 S  S1wBH3 Ca  ½Ca211½tATG5
WJ52wJNK 01S
WL52wBCEN1P 01½DAPK
WT5wMTOR 02½Ca21
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Apoptosis in our model is an all-or-none commitment of
individual cells because we assume that MOMP is gov-
erned by a bistable switch. As described in ref.19, the
switch is flipped from the “living” state to the “dying” state
when [BH3] exceeds [BCL2mit] in the mitochondrial outer
membrane. The all-or-none nature of the transition in the
model is reflected in the fact that most cells survive for C <
5 and most cells die for C > 6. For 5 < C < 6; only a frac-
tion of cells die because of the lognormal distribution we
assume for [BCL2mit]. Experimental confirmation of the
“threshold” effects in Figure 2d,e provide strong support for
a “bistable switch” underlying MOMP, an assumption of the
model that is still a subject of some disagreement among
theoreticians.19,20
Quantitative comparison of the model to autophagy
and apoptosis in populations of RPT cells
For quantitative comparison, we chose an “optimal” set of
parameter values (Table 3) to best fit the data (Supple-
mentary Table S1), as detailed in Supplementary
Text S3. Recognizing that the available data are insufficient
to constrain the values of all the parameters in our model,
we generated a collection of 3,758 parameter sets that also
provided good fits to the data. Simulations using these
acceptable parameter sets enable us to compute error bars
for our simulation results.
In Figure 3a, we plot the model’s prediction of autophagy
level in response to a cisplatin dose of 20 lM (C 5 20).
For each of the acceptable parameter sets, we simulated
the response of 100 cells, each with a particular value of
[BCL2mit]. For each parameter set, we compute, from the
sample of 100 cells, the mean value of [ATPHG](t) and the
percentage of apoptotic cells at each point in time. Then,
from the sample of 3,758 acceptable parameter sets, we
plot the mean (black line) 6 one standard deviation of
autophagy and percent apoptosis as functions of time. The
simulations compare very favorably with the experimental
data (circles) from figure 6d of Periyasamy-Thandavan
et al.18 The experimental points are singlets and said, by
the authors, to be “representative of at least three separate
experiments.” To get an idea of the variability of these
measurements, one should compare figures 1a, 4d, 5d,
and 6d in ref.18. In these experiments, the level of autoph-
agy increases to a maximum at 6 hours, after which neg-
ative feedback from Ca21 causes the level of autophagy to
decrease. As cells become apoptotic, the average level of
Table 3 Parameters, their descriptions, their optimal values, and their coefficients of variation over the collection of acceptable parameter sets
Parameters Description Optimal valuesa Coeff. var.a
C Function of cisplatin dose 0
ka; kda Rate constants for autophagosome formation and degradation (h
21) 1.77, 0.0948 15%, 14%
kc Drug-induced stress rate (lM
21 h21) 0.51 14%
kcasp Rate constant for Beclin-1 cleavage by Caspase (h
21) 2.01 16%
kin; kout Rate constants for Ca
21 transport from ER to cytoplasm and vice versa (h21) 9.64, 6.31 14%, 14%
kra Rate constant for autophagic relief of stress (h
21) 3.83 18%
krb Rate constant for background relief of stress (h
21) 1.41 13%
ksb Basal rate of stress (h
21) 2.08 13%
wATG5 0;wATG13 0 Offsets of sigmoidal function when there are no signals 0.215, 0.144 15%, 11%
wBCL2P 0;wBECN1P 0 0.614, 0.647 11%, 10%
wBH3 0;wCALP 0 1.26, 0.514 8%, 10%
wDAPK 0;wJNK 0 2.98, 1.22 15%, 12%
wMTOR 0 0.202 15%
wBH3 S;wBH3 Ca Interaction coefficients 0.08, 0.0003 18%, 15%
cA; cB Rate constants for changes in protein concentrations (h
21) 0.524, 5.21 13%, 14%
1.95, 4.05 15%, 13%cC; cD
1.04, 0.01 17%, 19%
1.73, 3.43 11%, 16%
cG; cH
cJ; cL
1.61 13%cT
rA; rB Steepness of sigmoidal response curves 4.83, 4.57 14%, 11%
rC; rD 32.3, 1.01 14%, 15%
rG; rH 20.8, 2.89 12%, 12%
rJ; rL 2.42, 7.99 16%, 17%
rT 3.51 12%
½BCL2ER Total BCL-2 family proteins in ER 3 fixed
½BCL2mit Total antiapoptotic BCL-2 family proteins in mitochondria
(lognormally distributed)
Mean 5 0.120
SD 5 0.0292
fixed
fixed
½Ca21T Maximum cytoplasmic [Ca21 ] due to release of ER calcium 2 fixed
½IP3RT Total IP3R proteins in ER 1 fixed
aC(popt) 5 0.5364, where C(p) 5 cost function defined in Suppl. Text S2, for a parameter vector p.
bCoefficient of variation 5 (SD) / jmeanj. Note: the mean value of a parameter 6¼ its optimal value.
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autophagy drops further. The time course of apoptosis in
our simulated population (Figure 3b) is in good agreement
with the experimental observations in figure 1e of
Periyasamy-Thandavan et al.18
Experiments by Periyasamy-Thandavan et al.18 (their
figure 5d) show that BCL-2 overexpression not only
decreases the basal level of autophagy but also blocks
the activation of autophagy after treatment with 20 lM
cisplatin (Figure 3a, lower curves). To simulate this
experiment, we increased BCL-2 expression by 3-fold in
both the ER and mitochondria. The reduced autophagic
response (in the model) is due to excess BCL-2 protein
binding Beclin-1 and preventing initiation of autophagy. At
the same time, cell death is also inhibited because the
higher BCL-2 level in mitochondria cannot be over-
whelmed by the elevated levels of BH3 in response to
cisplatin treatment.
Inhibition of autophagosome docking
The key function of autophagosomes is to engulf damaged
cellular material and then fuse with lysosomes, where the
collected material is degraded and recycled. Bafilomycin
(BAF) is widely used to block the fusion of autophago-
somes with lysosomes, resulting in accumulation of auto-
phagosomes in the cytoplasm. Figure 3c displays the
increased accumulation of autophagosomes in both experi-
ment and simulation after cells were treated with 20 lM cis-
platin in combination with 100 nM BAF. To simulate the
effect of BAF treatment in the model, both the absorption
rate of autophagosomes (kda) and (consequently) the rate
of stress reduction by autophagy (kra) are reduced 5-fold. It
is interesting to note that, when cells are challenged with
20 lM cisplatin 1 100 nM BAF, the maximum autophagy
level is the same as that observed with 20 lM cisplatin
alone, although cells treated with BAF should have much
Figure 2 Qualitative properties of the model. (a,b) Simulated time course of the autophagy–apoptosis model for an “average” cell with
[BCL2mit] 5 0.12. The equations in Table 2 are solved using the optimal parameter values in Table 3, given the initial conditions in
Table 1, with C 5 20, for 0  t  15. Each curve is plotted in terms of an arbitrary “unit” U, as follows: UATG55 0.9, UATG135 0.8,
UATPHG 5 1, UBCL2-P 5 2.5, UBECNP 5 2.3, UBH35 1, UCalpain 51, UCytCa 5 1.2, UDAPK 5 1.5, UIP3RF 5 1.2, UJNK 5 1.3, UmTOR 5
0.3, UStress 5 13. (c) Simulated time course of the relative level of autophagy, [ATPHG](t)/[ATPHG](0), in an “average” cell, with
[BCL2mit] 5 0.12, for different levels of stressor, C, from 0 to 100. (d) Mean relative level of autophagy at t 5 100 hours, in a population
of 100 cells, with a lognormal distribution of [BCL2mit], as a function of increasing stressor, C. For low doses of cisplatin (C < 5), the
mean level of autophagy increases steadily to counter the effects of cisplatin-induced stress. For 5 < C < 6, autophagy cannot relieve
the stress in all 100 cells and some of them commit apoptosis. For C > 6, all cells are apoptotic and [ATPHG] 5 0 by t 5 100. (e) Per-
centage of apoptotic cells (in a population of 100 cells with lognormally distributed [BCL2mit]) at particular timepoints after stimulation,
as functions of increasing levels of stressor, C.
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higher stress than cells treated without BAF. In the model,
higher stress strongly activates calpain, which cleaves
ATG5 and limits the maximum level of autophagy. If calpain
is inhibited, cells are observed to die by excess autoph-
agy,43 and we see a massive increase in autophagy when
calpain is inhibited in a simulated treatment with 20 lM cis-
platin 1 100 nM BAF (Supplementary Figure S2). This
role of calpain may have evolved to avert autophagic death
in cells subjected to high stress.
Impaired fusion of autophagosomes with lysosomes puts
the cell under increased stress and should lead to
increased apoptosis. In the experiment, 55% of cells were
apoptotic at 12 hours, compared to 53% of the simulated
cells (Figure 4a). The model predicts that 89% of cells will
be apoptotic at 24 hours (Figure 4b).
Inhibition of autophagosome formation
3-MA inhibits formation of autophagosomes. In response
to treatment with 20 lM cisplatin 1 10 mM 3-MA, both
experiments and simulations show a decreased level of
autophagy (Figure 3d) compared to treatment with 20 lM
cisplatin alone (Figure 3a). To simulate the effect of 3-
MA, the parameter controlling formation of autophago-
somes (ka) was decreased 2-fold. As with BAF, the
decrease in autophagic recycling of cellular material
caused by 3-MA should increase cell death. Experimen-
tally, 46% of cells were apoptotic at 12 hours compared to
38% of the simulated cells at this point (Figure 4a). The
level of apoptosis is not quite as high as for BAF treat-
ment, suggesting higher autophagic recycling in the case
of 3-MA treatment. Similarly, inhibition of autophagy, by
knocking down Beclin-1 while treating cells with 20 lM
cisplatin, also results in increased apoptosis, both experi-
mentally (55% at 16 hours) and in simulation (57%). (In
the simulation, we reduced the initial value of [BECN1]T
by 50%.) As expected, the model predicts significantly
higher percentages of apoptotic cells at 24 hours in all
cases (Figure 4b). We suggest that future experiments
measuring apoptosis in cells responding to high cisplatin
stress be carried out to 24 hours and beyond, to deter-
mine whether most cells eventually commit apoptosis, as
predicted by our model (Figure 3e).
Our model also accounts for the proapoptotic effect of 3-
MA at a cisplatin dose of 5 lM (Figure 4a, as compared to
figure 7c of Periyasamy-Thandavan et al.18). Because very
few cells commit apoptosis at a dose of 5 lM cisplatin, we
Figure 3 Time courses of autophagy and apoptosis under cisplatin treatment. In each panel we simulate an experiment from
Periyasamy-Thandavan et al.18 (circles and squares) by solving the equations in Table 2 using 3,758 different sets of parameter values
in the collection of “acceptable” parameter sets, as described in the text and the Supplementary Material. The black line plots the
mean level of autophagy across all 3,758 simulations, and the gray region spans one standard deviation above and below the mean.
(a) Time courses of LC3-II and autophagy level for 24-hour treatment with 20 lM cisplatin alone (circles and solid line) and in conjunc-
tion with BCL-2 overexpression (squares and dashed line). The experimental data (“representative of at least three separate
experiments”) are replotted from Periyasamy-Thandavan et al.18 (circles from their figure 6d; squares from their figure 5d). In both sim-
ulations, C 5 20; for the case of BCL-2 overexpression, [BCL2ER] 5 9 and the mean value of [BCL2mit] 5 0.36 in the simulation.
(b) Time course of percentage apoptotic cells (circles from figure 1e of Periyasamy-Thandavan et al.18). (c) Time course of LC3-II
(circles from figure 6d of Periyasamy-Thandavan et al.18) and simulated autophagy level for 24-hour treatment with 20 lM cisplatin 1
100 nM Bafilomycin (optimal value of kda 5 0.019 h
21 and optimal value of kra 5 0.77 h
21 in the simulation). (d) Time course of LC3-II
(circles from figure 6d of Periyasamy-Thandavan et al.18) and simulated autophagy level for 24-hour treatment with 20 lM cisplatin 1
10 mM 3-methyladenine (optimal value of ka 5 0.88 h
21 in the simulation).
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cannot associate this dose with C 5 5, which lies at the
cusp of life-or-death in our model. Although the model was
parameterized to fit data at a cisplatin dose of 20 lM with
C 5 20, there is no reason to expect that the parameter C,
which measures metabolic stress, should bear a linear rela-
tion to cisplatin dose. Hence, we choose C 5 2.5, where
cells are robustly surviving in the model, to represent the
case of cisplatin 5 5 lM in experiments.
To see how all variables of an “average” cell respond to
all the experimental conditions considered in this section,
see Supplementary Figure S1.
DISCUSSION
Recent advances in molecular cell biology indicate that
anticancer therapies promote cellular stress, which can trig-
ger both autophagy and apoptosis.3,44 Hence, understand-
ing the interactions among the molecular regulators of
these major cell survival/death pathways is critical to solv-
ing clinical issues associated with drug efficacy and side
effects. In this study, we show that a mathematical model
of cellular stress can capture the prosurvival and prodeath
responses of cells in qualitative terms and be fitted accu-
rately to quantitative time-course data of autophagy and
apoptosis measured by Periyasamy-Thandavan et al.18
The model predicts the time courses of regulatory proteins
(Figure 2a,b) and the long-term extent of apoptosis
(Figures 2e and 4b), which were not measured in the origi-
nal experiments. The model predicts that, for the rat kidney
cells studied here, the role of cytoplasmic calcium ions in
upregulating apoptosis proceeds less through calcineurin’s
activation of proapoptotic proteins than through calpain’s
truncation of ATG5. Future quantitative measurements of
how cells respond to cytotoxic stress will allow us to test
this model and build new versions with more predictive
power. In addition, experiments that interfere with apoptosis
in cells responding to cisplatin, e.g., by manipulating apo-
ptosis activators and inhibitors, such as second
mitochondria-derived activator of caspases (SMAC) and X-
linked inhibitor of apoptosis protein (XIAP), will provide data
to further support and improve the model.
Cell stress responses, such as autophagy and apoptosis,
are central to determining the responses of cancer patients
to pharmacological interventions. For example, autophagy
is commonly associated with the acquisition of drug resist-
ance by cancer cells and contributes to the poor patient
survival rate of many cancers. On the positive side, autoph-
agy plays a cytoprotective role in cisplatin nephrotoxicity.
Because autophagy and apoptosis are governed by an intri-
cate dynamic network of interacting proteins, it is imperative
to identify and target key components of this network when
designing therapeutic regimens for diseases such as can-
cer.45–47 An accurate, cancer-specific mathematical model
can advance the pharmacodynamic analysis of prospective
anticancer agents and help find novel combinations of exist-
ing therapies that increase the death of cancer cells using
low doses that spare normal cells.
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Figure 4 Percentage of apoptotic cells. (a) Percentage of apoptotic cells (mean 6 one standard deviation) in experiment (light gray
bars) and simulation (medium gray bars) under various treatments at the indicated timepoint. The experimental data are replotted
from Periyasamy-Thandavan et al.18 (their figures 7b,c and 8d). “Four fields with 200 cells per field were evaluated in each dish to
estimate the percentage of cells with typical apoptotic morphology.” The simulations are done as described in the legend to Figure 3.
(b) For each of the experimental conditions in panel (a), we plot the percentage of apoptotic cells (mean 6 one standard deviation) in
simulations at 12 hours (light gray), 16 hours (medium gray), and 24 hours (dark gray). The 24-hour timepoints are predictions of the
model.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Autophagy and apoptosis regulate cell fate in response to
stress. Experimental studies provide quantitative data
on cell survival and death in response to stress. But no
computational models have yet attended to the dynami-
cal interplay of autophagy and apoptosis in relation to
the experimental data.
WHAT QUESTIONS DID THIS STUDY ADDRESS?
 Can a simple mathematical model of the regulation of
autophagy and apoptosis effectively account for the
observed responses of rat cells to exposure to the cyto-
toxic drug cisplatin?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Since the model presented here is consistent with the
data used for its validation, it provides an initial step
towards better understanding of the complex interac-
tions among cell fate pathways.
HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS
 Optimizing therapeutic protocols, especially those involving
multiple drugs, will require a detailed understanding of the
balance between survival and death in both diseased and
normal cells. Dynamic models, such as the autophagy-
apoptosis model presented here, can play a key role in
understanding and computing optimal protocols.
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